Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: PaperChase who wrote (85674)	11/18/2000 10:30:58 AM
From: tom r. phillips	Respond to of 132070

PaperChase -- i'll take a look at IMA. thanks. re. reimbursement: the Health Care Finance Administration just raised reimbursement rates for EECP sessions (one hour) 11% to $144 (for Medicare; most private insurers will automatically follow). at that rate, a $180,000 piece of equipment generating income for 2000 hours per year will produce $288,000 of revenue for a clinic, etc. biz.yahoo.com here's a post from yahoo (somewhat vague): "VASO is a one product company with a cache. The one product they have patents and copyrights and ect. is classed as a Class III PMA device. VASO has taken 10 yrs to get where they are. A massive amount of research has gone into their product. Any manufacturer hoping to cash in on the success of EECP will have to start from square one to prove they can compete with EECP's results. This type of device is not similar to aphone modem it has to be proven to be accepted. So far that has taken VASO 10 yrs. This gives VASO a minimum 2-3 yr lead and followers won't be able to piggyback VASO's results. Right now there is only one competitor to VASO - Cardiomedics. There technique compares so poorly to EECP that they refuse to release any data. Accounts receivable is high but they always have been because VASO gives terms better than 30 days. " Tom